AAHRPP Lengthens Reaccreditations, Tightens Compliance Policies

The Association for the Accreditation of Human Research Protection Programs (AAHRPP) is extending its reaccreditation period for drug sponsors and institutional review boards while tightening some of its other compliance policies. AAHRPP lengthened the current reaccreditation period from three years to five, beginning Jan. 1. “We want to reduce the burden on organizations, so they can spend more time doing what they have to do in order to remain accredited,” AAHRPP spokesman David Ward said.
Drug Industry Daily